Advertisement

Clinical Rheumatology

, Volume 37, Issue 7, pp 2011–2012 | Cite as

Letter to the Editor: Time for cost-effectiveness studies for preventive strategies applied according to risk of cytomegalovirus-related morbidity and mortality in ANCA-associated vasculitis

  • Cynthia C. Lim
  • Irene Y. J. Mok
  • Jason C. J. Choo
Letter to the Editor

Abstract

Gastrointestinal cytomegalovirus (CMV) disease in ANCA-associated vasculitis is associated with significant morbidity. Studies should be performed to identify the epidemiology and risk factors for CMV disease in AAV so that vulnerable patients may be risk-stratified for consideration of preventive strategies such as surveillance and pre-emptive therapy or anti-viral prophylaxis. Given the absence of evidence-based guidelines for prevention of CMV disease in patients with AAV receiving potent immunosuppressive therapy, further risk-benefit studies are required to ascertain if preventive strategies will reduce CMV-related morbidity and mortality in individuals with AAV.

Keywords

Cyclophosphamide Immunosuppressive agents Methylprednisolone Prophylaxis 

Notes

Compliance with ethical standards

Disclosure

Jason Choo has served on Advisory Boards for Novartis and Pfizer with donation of honorarium to Singapore General Hospital to support research and education.

References

  1. 1.
    Soriano A, Smerieri N, Bonilauri S, de Marco L, Cavazza A, Salvarani C (2018) Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression. Clin Rheumatol.  https://doi.org/10.1007/s10067-017-3945-6
  2. 2.
    Lee KG, Teo SH, Lim C, Loh A, Chidambaram V, Choo J (2016) Severe gastrointestinal cytomegalovirus disease in two patients with renal vasculitis after immunosuppression. Clin Nephrol 86(9):154–161CrossRefPubMedGoogle Scholar
  3. 3.
    Lim CC, Tung YT, Tan BH, Lee PH, Mok IYJ, Oon L, Chan KP, Choo JCJ (2017) Epidemiology and risk factors for cytomegalovirus infection in glomerular diseases treated with immunosuppressive therapy. Nephrology (Carlton).  https://doi.org/10.1111/nep.13071
  4. 4.
    Kotton CN, Kumar D, Caliendo AM, Åsberg A, Chou S, Danziger-Isakov L, Humar A (2013) Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96(4):333–360CrossRefPubMedGoogle Scholar
  5. 5.
    Chanouzas D, Dyall L, Nightingale P, Ferro C, Moss P, Morgan MD, Harper L (2016) Valaciclovir to prevent cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis: study protocol for a randomised controlled trial. Trials 17(1):338CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  1. 1.Department of Renal MedicineSingapore General HospitalSingaporeSingapore

Personalised recommendations